The International Association for the Study of Lung Cancer
The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.
ILCN In Focus
Resources for Reading & Understanding Biomarker Test Results
Biomarker test results are crucial for lung cancer patients to understand, but they are difficult to read due to their complexity. The Advanced Practitioner Society for Hematology and Oncology, the Association of Community Cancer Centers, the Association for Molecular Pathology, and LUNGevity Foundation created basic and comprehensive education for ALL non-small cell lung cancer patients to understand their results. Materials are available in English and Spanish. Learn more.
IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective.
IASLC's Corporate Roundtable
Born from feedback received during meetings with our Corporate Partners in 2022, the IASLC Corporate Roundtable brings IASLC leadership and Roundtable Member Representatives together to collaborate on solutions to big-picture challenges facing those working to conquer lung cancer and other thoracic malignancies.
Journal of Thoracic Oncology & JTO Clinical and Research Reports
Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.